Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches
Open accessAbstract
Background: Growing evidence suggests psilocybin, a naturally occurring psychedelic, is a safe and promising pharmacotherapy for treatment of mood and substance use disorders when administered as part of a structured intervention. In most trials to date, psilocybin dose has been administered on a weight-adjusted basis rather than the more convenient procedure of administering a fixed dose. Aims: The present post hoc analyses sought to determine whether the subjective effects of psilocybin are affected by body weight when psilocybin is administered on a weight-adjusted basis and when psilocybin is administered as a fixed dose. Methods: We analyzed acute subjective drug effects (mystical, challenging, and intensity) associated with therapeutic outcomes from ten previous studies (total N = 288) in which psilocybin was administered in the range 20 to 30 mg/70 kg (inclusive). Separate multivariate regression analyses examined the relationships between demographic variables including body weight and subjective effects in participants receiving 20 mg/70 kg ( n = 120), participants receiving 30 mg/70 kg ( n = 182), and participants whose weight-adjusted dose was about 25 mg (to approximate the fixed dose that is currently being evaluated in registration trials for major depressive disorder) ( n = 103). Results: In the 20 mg/70 kg and 30 mg/70 kg weight-adjusted groups, and in the fixed dose group, no significant associations were found between subjective effects and demographic variables including body weight or sex. Across a wide range of body weights (49 to 113 kg) the present results showed no evidence that body weight affected subjective effects of psilocybin. Conclusions: These results suggest that the convenience and lower cost of administering psilocybin as a fixed dose outweigh any potential advantage of weight-adjusted dosing.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Body weight has no influence on subjective effects of psilocybin in humans.
“following evidence that body weight has no influence on psilocybin pharmacokinetics [71] and subjective effects [72] in humans.”
From Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial (2024) · cites this paper as [72]
The Results report no significant association between body weight and subjective effects, and the Discussion says the findings strongly suggest weight is not a major factor. But the Discussion also says the analyses did not provide definitive evidence; the categorical claim that body weight has no influence overstates the finding. (LLM, conf=0.86)
Experimental — accuracy not yet measuredOur participants reported intense psychedelic experiences comparable with other studies in non-substance use disorder populations.
“In contrast, our participants reported intense psychedelic experiences comparable with other studies in non-substance use disorder populations [57].”
From Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study. (2025) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
<b>lavaan</b> : An <i>R</i> Package for Structural Equation Modeling
Rosseel, Y. (2012) · Journal of Statistical Software · doi:10.18637/jss.v048.i02 · Cited by 27,955 · see citing works
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 8× · see citing works
“…seeking to quit smoking (Johnson et al., 2014, 2017), patients with a life-threatening cancer diagnosis and symptoms of anxiety or depression (Griffiths et al., 2016), novice meditators (Griffiths et al., 2018), meditation practitioners with a long-term daily practice (clinicaltrials.gov:…”
BackgroundMethodInfluentialSelf-citationNichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762 · see citing works
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698 · see citing works
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · see citing works
Self-citationCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · see citing works
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301 · see citing works
Self-citationSex differences in emotion: Expression, experience, and physiology.
Kring, A. M., & Gordon, A. H. (1998) · Journal of Personality and Social Psychology · doi:10.1037//0022-3514.74.3.686 · Cited by 1,289 · see citing works
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · see citing works
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · see citing works
Sex differences in emotion: Expression, experience, and physiology.
Kring, A. M., & Gordon, A. H. (1998) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.74.3.686 · Cited by 1,067 · cited 1× · see citing works
“It is possible that women were more likely to report feelings such as grief and physical distress than their male counterparts or felt more comfortable disclosing these due to cultural norms or expectations (e.g.,Kring and Gordon, 1998).”
BackgroundPsilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970 · see citing works
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932 · see citing works
Self-citationPilot study of the 5-HT <sub>2A</sub> R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 5× · see citing works
“Recent open-label pilot studies have found psilocybin to be a potentially effective aid for treatment of depression (Carhart-Harris et al., 2016, 2017, 2018; Davis et al., 2020), alcohol dependence (Bogenschutz et al., 2015), and tobacco dependence (Johnson et al., 2014, 2017).”
BackgroundInfluentialSelf-citationGriffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905 · see citing works
Self-citationMacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895 · see citing works
Self-citationRoseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808 · see citing works
Long-term follow-up of psilocybin-facilitated smoking cessation
Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2016.1170135 · Cited by 696 · see citing works
Self-citationValidation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115609019 · Cited by 637 · see citing works
Self-citationPsilocybin for treatment-resistant depression: fMRI-measured brain mechanisms
Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., Tanner, M., Kaelen, M., McGonigle, J., Murphy, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13282-7 · Cited by 587 · see citing works
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., Jesse, R., MacLean, K. A., Barrett, F. S., Cosimano, M. P., & Klinedinst, M. A. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117731279 · Cited by 520 · see citing works
Self-citationCarbonaro, T. M., Bradstreet, M. P., Barrett, F., Maclean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116662634 · Cited by 494 · see citing works
Self-citationHartogsohn, I. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116677852 · Cited by 483 · see citing works
Psilocybin-Occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107121331 · Cited by 476 · see citing works
Self-citationMacLean, K. A., Leoutsakos, J. S., Johnson, M. W., & Griffiths, R. R. (2012) · Journal for the Scientific Study of Religion · doi:10.1111/j.1468-5906.2012.01685.x · Cited by 405 · see citing works
Self-citationEmotions and brain function are altered up to one month after a single high dose of psilocybin.
Barrett, F. S., Doss, M. K., Sepeda, N. D., Pekar, J. J., & Griffiths, R. R. (2020) · Scientific Reports · doi:10.1038/s41598-020-59282-y · Cited by 375 · see citing works
Self-citationPrediction of Psilocybin Response in Healthy Volunteers
Studerus, E., Gamma, A., Kometer, M., & Vollenweider, F. X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030800 · Cited by 369 · see citing works
Barrett, F. S., Bradstreet, M. P., Leoutsakos, J.-M. S., Johnson, M. W., & Griffiths, R. R. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116678781 · Cited by 366 · cited 1× · see citing works
“The Challenging Experience Questionnaire (CEQ) is a 26-item measure assessing seven dimensions of psychedelic-occasioned challenging experiences: grief, fear, death, insanity, isolation, physical distress, and paranoia, with each dimension comprising a CEQ subscale (Barrett et al., 2016).”
BackgroundSelf-citationGender differences in the subjective effects of MDMA
Liechti, M. E., Gamma, A., & Vollenweider, F. X. (2001) · Psychopharmacology · doi:10.1007/s002130000648 · Cited by 360 · see citing works
Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature.
Michaels, T. I., Purdon, J., Collins, A., & Williams, M. T. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1824-6 · Cited by 265 · see citing works
The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis
Goldberg, S. B., Pace, B. T., Nicholas, C. R. N., Raison, C. L., & Hutson, P. R. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.112749 · Cited by 231 · see citing works
Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults
Brown, R. T., Nicholas, C. R., Cozzi, N. V., Gassman, M. C., Cooper, K. M., Muller, D., Thomas, C. D., Hetzel, S. J., Henriquez, K. M., Ribaudo, A. S., et al. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0540-6 · Cited by 188 · see citing works
Madsen, M. K., Fisher, P. M., Stenbæk, D. S., Kristiansen, S., Burmester, D., Lehel, S., Páleníček, T., Kuchař, M., Svarer, C., Ozenne, B., et al. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.02.001 · Cited by 183 · see citing works
Carbonaro, T. M., Johnson, M. W., Hurwitz, E., & Griffiths, R. R. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4769-4 · Cited by 133 · see citing works
Self-citationBarrett, F. S., Carbonaro, T. M., Hurwitz, E., Johnson, M. W., & Griffiths, R. R. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4981-x · Cited by 109 · see citing works
Self-citationNeuroticism is associated with challenging experiences with psilocybin mushrooms
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2017) · Personality and Individual Differences · doi:10.1016/j.paid.2017.06.004 · Cited by 98 · see citing works
Self-citationBrain serotonin 2A receptor binding: Relations to body mass index, tobacco and alcohol use
Erritzøe, D., Frøkjær, V. G., Haugbøl, S., Marner, L., Svarer, C., Holst, K. K., Baaré, W. F. C., Rasmussen, P. M., Madsen, J., Paulson, O. B., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.01.050 · Cited by 90 · see citing works
Weight-based dosing in medication use: what should we know?
Zhou, Q., Pan, S., Zhu, L., Chen, M., & Xia, P. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s103156 · Cited by 65 · see citing works
Nisbet, M. C., & Fahy, D. (2013) · BMC Medical Ethics · doi:10.1186/1472-6939-14-10 · Cited by 35 · see citing works
Henningfield, J. E., Fields, S. A., Anthony, J. C., Brown, L. S., Bolaños‐Guzmán, C. A., Comer, S. D., Garza, R. D. L., Furr-Holden, D., Garcia‐Romeu, A., Hatsukami, D. K., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0784-y · Cited by 12 · see citing works
Self-citation
Flagged first, then by citations
1 of the 41 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
The Therapeutic Potential of Psilocybin
Lowe, H. I. C., Toyang, N., Steele, B., Valentine, H., Grant, J. F., Ali, A., Ngwa, W., & Gordon, L. (2021) · Molecules · doi:10.3390/molecules26102948 · Cited by 206 · see citing works
Holze, F., Ley, L., Müller, F., Becker, A. M., Straumann, I., Vizeli, P., Kuehne, S. S., Roder, M. A., Duthaler, U., Kolaczynska, K. E., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01297-2 · Cited by 226 · see citing works
“The body weight adjustment of the psilocybin dose did not alter subjective effects and had no advantages [42], and fixed dosing is more practical in large trials in patients.”
BackgroundBecker, A. M., Holze, F., Grandinetti, T., Klaiber, A., Toedtli, V. E., Kolaczynska, K. E., Duthaler, U., Varghese, N., Eckert, A., Grünblatt, E., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2487 · Cited by 184 · see citing works
Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study
Cavanna, F., Muller, S. L., de la Fuente, L. A., Zamberlán, F., Palmucci, M., Janeckova, L., Kuchař, M., Pallavicini, C., & Tagliazucchi, E. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02039-0 · Cited by 148 · see citing works
“While this adjustment might not be necessary for larger doses, its importance for microdosing remains unexplored [69].”
BackgroundTherapeutic effect of psilocybin in addiction: A systematic review
van der Meer, P. B., Fuentes, J. J., Kaptein, A. A., Schoones, J. W., de Waal, M. M., Goudriaan, A. E., Kramers, K., Schellekens, A., Somers, M., Bossong, M. G., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1134454 · Cited by 127 · see citing works
“In addition, all the included studies in this systematic review adjusted psilocybin dose to body weight, (25–30) although there is no clear benefit for this adjustment and fixed dosing is more practical in clinical trials (35, 36).”
BackgroundPharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants
Holze, F., Becker, A., Kolaczynska, K. E., Duthaler, U., & Liechti, M. E. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2821 · Cited by 119 · see citing works
McCulloch, D. E.-W., Knudsen, G. M., Barrett, F. S., Doss, M. K., Carhart-Harris, R. L., Rosas, F. E., Deco, G., Kringelbach, M. L., Preller, K. H., Ramaekers, J. G., et al. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104689 · Cited by 108 · see citing works
Self-citationTherapeutic use of psilocybin: Practical considerations for dosing and administration
MacCallum, C. A., Lo, L. A., Pistawka, C. A., & Deol, J. K. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1040217 · Cited by 102 · see citing works
Nayak, S. M., Jackson, H., Sepeda, N. D., Mathai, D. S., So, S., Yaffe, A., Zaki, H., Brasher, T. J., Lowe, M. X., Jolly, D. R. P., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1199642 · Cited by 93 · see citing works
“Subjective effects ratings were lower and yielded a smaller proportion of “complete” mystical experience than those found in laboratory research administering 20 mg/70 kg or 30 mg/70 kg psilocybin (57).”
BackgroundSelf-citationBender, D., & Hellerstein, D. J. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06049-6 · Cited by 88 · see citing works
Neural Mechanisms and Psychology of Psychedelic Ego Dissolution
Stoliker, D., Egan, G. F., Friston, K. J., & Razi, A. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000508 · Cited by 89 · see citing works
Thrul, J., & Garcia‐Romeu, A. (2021) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2021.1897331 · Cited by 80 · see citing works
“Pooled analyses of contemporary clinical trials on psychedelics have found that white individuals comprise large majorities (>80%) of study participants, substantially underrepresenting BIPOC, and calling into question the generalizability of findings to non-white populations and equity of access to such trials (Garci…”
BackgroundSelf-citationPsychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69 · see citing works
Pharmacokinetics of N,N-dimethyltryptamine in Humans
Good, M., Joel, Z., Benway, T. A., Routledge, C. A., Timmermann, C., Erritzøe, D., Weaver, R., Allen, G., Hughes, C., Topping, H., et al. (2023) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-023-00822-y · Cited by 67 · see citing works
Wießner, I., Olivieri, R., Falchi-Carvalho, M., Palhano-Fontes, F., Maia, L. O., Feilding, A., de Araújo, D. B., Ribeiro, S. T. G., & Tófoli, L. F. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.01.114 · Cited by 44 · see citing works
Assessment of the Acute Effects of 2C‐B vs. Psilocybin on Subjective Experience, Mood, and Cognition
Mallaroni, P., Mason, N. L., Reckweg, J. T., Paci, R., Ritscher, S., Toennes, S. W., Theunissen, E. L., Kuypers, K. P. C., & Ramaekers, J. G. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2958 · Cited by 39 · see citing works
Yu, C., Liang, C., Yang, F., Tu, Y., Hsu, C., Carvalho, A. F., Stubbs, B., Thompson, T., Tsai, C., Yeh, T., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11040938 · Cited by 38 · see citing works
“This result implies that body mass index may affect the optimal dose [38]; however, neither weight-adjusted nor fixeddosing of psilocybin showed a significant impact on subjective drug effects with clinical relevance [39].”
BackgroundPsilocybin’s effects on cognition and creativity: A scoping review
Bonnieux, J. N., VanderZwaag, B., Premji, Z., Garcia‐Romeu, A., & García-Barrera, M. A. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231179801 · Cited by 35 · see citing works
“Psilocybin was most often administered orally (83%), and dosages were typically body weight-adjusted (74%) despite recent research suggesting this to be unnecessary (Garcia-Romeu et al., 2021).”
BackgroundSelf-citationLiechti, M. E., & Holze, F. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_270 · Cited by 35 · see citing works
The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns
Johnston, C. B., Mangini, M., Grob, C. S., & Anderson, B. T. (2022) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2022.08.007 · Cited by 33 · see citing works
Minorities’ diminished psychedelic returns
Viña, S. M., & Stephens, A. L. (2023) · Drug Science Policy and Law · doi:10.1177/20503245231184638 · Cited by 31 · see citing works
“…have found that White individuals comprise over 80% of study participants, substantially underrepresenting BIPOC, and according to Thrul and Garia-Romeu (2021), call into question the generalizability of fi ndings to non-White populations (Garcia-Romeu et al., 2021; Michaels et al., 2018).”
BackgroundAre Psychedelic Medicines the Reset for Chronic Pain? Preliminary Findings and Research Needs
Zia, F., Baumann, M., Belouin, S., Dworkin, R., Ghauri, M. H., Hendricks, P. S., Henningfield, J., Lanier, R., Ross, S., & Berger, A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109528 · Cited by 26 · see citing works
Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review
Chisamore, N., Johnson, D. E., Chen, M. J. Q., Offman, H., Chen-Li, D. C. J., Kaczmarek, E. S., Doyle, Z., McIntyre, R. S., & Rosenblat, J. D. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.05.051 · Cited by 26 · see citing works
Do the therapeutic effects of psilocybin involve actions in the gut?
Reed, F. M., & Foldi, C. J. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.12.007 · Cited by 24 · see citing works
Predictors and potentiators of psychedelic-occasioned mystical experiences
Gandy, S. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00198 · Cited by 26 · see citing works
Kolasa, M., Nikiforuk, A., Korlatowicz, A., Solich, J., Potasiewicz, A., Dziedzicka‐Wasylewska, M., Bugno, R., Hogendorf, A. S., Bojarski, A. J., & Faron‐Górecka, A. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06644-3 · Cited by 23 · see citing works
Set and setting in microdosing: an oft-overlooked principle
Hartogsohn, I., & Petranker, R. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06249-8 · Cited by 22 · see citing works
“For example, the relationship between dose and effect is yet unclear and unlike other pharmacological agents, is not directly predicted by body weight (Garcia-Romeu et al. 2021), and optimal dosing regimens are yet unknown.”
BackgroundRaithatha, S. A., Hagel, J. M., Matinkhoo, K., Yu, L. X., Press, D., Cook, S. G., Sharma, G., Dhananjaya, D., Jensen, G., Lee, J. B., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01225 · Cited by 22 · see citing works
Aday, J. S., McAfee, J., Conroy, D. A., Hosanagar, A., Tarnal, V., Weston, C. L., Scott, K., Horowitz, D., Geller, J. A., Harte, S. E., et al. (2025) · Frontiers in Pain Research · doi:10.3389/fpain.2025.1527783 · Cited by 21 · see citing works
Viña, S. M. (2024) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-024-02023-y · Cited by 21 · see citing works
“This underrepresentation raises concerns about the generalizability of findings to non-white populations [24, 53].”
Jensen, M. E., Stenbæk, D. S., Messell, C., Poulsen, E. D., Varga, T. V., Fisher, P. M., Nielsen, M. K. K., Johansen, S. S., Volkow, N. D., Knudsen, G. M., et al. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251319457 · Cited by 21 · see citing works
“…appear to impact the pharmacokinetics of plasma drug concentrations in healthy subjects (Holze et al., 2023) or subjective drug effects in cigarette smokers, in individuals with life-threatening cancers, and those with major depressive disorders (Garcia-Romeu et al., 2021; Spriggs et al., 2023).”
Body mass index (BMI) does not predict responses to psilocybin
Spriggs, M. J., Giribaldi, B., Lyons, T., Rosas, F. E., Kärtner, L., Buchborn, T., Douglass, H. M., Roseman, L., Timmermann, C., Erritzøe, D., et al. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221131994 · Cited by 18 · see citing works
“The present study also expands upon the results of previous studies (Garcia-Romeu et al., 2021; Studerus et al., 2011) by providing the first pooled analysis across studies employing a fixed dose of psilocybin.”
BackgroundMethodResultInfluentialPsilocybin: From Psychiatric Pariah to Perceived Panacea
Fonzo, G. A., Wolfgang, A. S., Barksdale, B. R., Krystal, J. H., Carpenter, L. L., Kraguljac, N. V., Grzenda, A. L., McDonald, W. M., Widge, A. S., Rodríguez, C. I., et al. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230682 · Cited by 16 · see citing works
Keeping the promise: a critique of the current state of microdosing research
Petranker, R., Anderson, T., Fewster, E. C., Aberman, Y., Hazan, M., Gaffrey, M. S., & Seli, P. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1217102 · Cited by 15 · see citing works
Psychedelics align brain activity with context
Stoliker, D., Novelli, L., Khajehnejad, M. A., Biabani, M., Greaves, M. D., Barta, T., Williams, M., Chopra, S., Bazin, O., Simonsson, O., et al. (2026) · Nature · doi:10.1038/s41586-026-10910-z · Cited by 16 · see citing works
“For machine-learning analyses (CEBRA, TAVRNN), participants were included only if all four conditions passed quality control with complete acquisition (expected volume count across the scanning session), giving a balanced sample of n = 54.”
Self-citationDowney, A. E., Chaphekar, A. V., Woolley, J. D., & Raymond‐Flesch, M. (2024) · Journal of Eating Disorders · doi:10.1186/s40337-024-01005-z · Cited by 14 · see citing works
“In post hoc analyses of studies with both body weight-adjusted and fixed dosing of psilocybin administrations across a wide range of body weight (49 kg to 113 kg), body weight did not significantly impact subjective drug effects or risk for adverse events [25].”
BackgroundMcCulloch, D. E.-W., Knudsen, G. M., Barrett, F. S., Doss, M. K., Deco, G., Carhart-Harris, R. L., Rosas, F. E., Preller, K. H., Ramaekers, J. G., Mason, N. L., et al. (2021) · doi:10.31234/osf.io/64kyg · Cited by 14 · see citing works
Self-citationVanderijst, L., Hever, F., Buot, A., Dauré, C., Benoit, J., Hanak, C., Veeser, J., Morgiève, M., Campanella, S., Kornreich, C., et al. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05502-y · Cited by 13 · see citing works
“Of note, relative doses have been mostly substituted with absolute doses, following evidence that body weight has no influence on psilocybin pharmacokinetics [71] and subjective effects [72] in humans.”
BackgroundAtiq, M. A., Baker, M. R., Voort, J. L. V., Vargas, M. V., & Choi, D. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06599-5 · Cited by 15 · see citing works
“…moderate dose: 20 mg/70 kg; high dose: 30 mg/70 kg), with parallels drawn to ‘The Varieties of Religious Experience’ described by William James in 1902 (Garcia-Romeu et al. 2021; Griffiths et al. 2006; James & Ralph Ellison Collection (Library of Congress), 1902; Johnson et al. 2014; Yaden &…”
Meccia, J., Lopez, J., & Bagot, R. C. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06297-0 · Cited by 13 · see citing works
Human behavioral pharmacology of psychedelics
Strickland, J. C., & Johnson, M. W. (2022) · Advances in pharmacology · doi:10.1016/bs.apha.2021.10.003 · Cited by 13 · see citing works
Self-citationMcGriff, S. A., Hecker, J. C., Maitland, A. D., Partilla, J. S., Baumann, M. H., & Glatfelter, G. C. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06795-x · Cited by 13 · see citing works
“Early clinical trials using psilocybin for treatment of various neuropsychiatric indica - tions administered oral doses ranging from 0.2 to 0.4 mg/ kg (Garcia-Romeu et al. 2021 ), whereas more recent trials used a fixed oral dose of 25 mg (MacCallum et al. 2022 ).”
InfluentialSyed, O. A., Petranker, R., Fewster, E. C., Sobolenko, V., Beidas, Z., Husain, M. I., Lake, S., & Lucas, P. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2424284 · Cited by 11 · see citing works
“The effects of psychedelics are difficult to predict as they are not affected by body weight (Garcia-Romeu et al. 2021; Spriggs et al. 2023).”
From Altered States to Metaphysics: The Epistemic Status of Psychedelic-induced Metaphysical Beliefs
Gładziejewski, P. (2023) · Review of Philosophy and Psychology · doi:10.1007/s13164-023-00709-6 · Cited by 11 · see citing works
Card, K. G., Grewal, A., Closson, K., Martin, G., Baracaldo, L., Allison, S., Kruger, D. J., & Walsh, Z. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2268640 · Cited by 10 · see citing works
“…feasibility studies suggest that psilocybin has good safety profile and low addiction potential (Hodge et al. 2023; Johnson et al. 2018), particularly at low doses (Garcia-Romeu et al. 2021; Henríquez-Hernández et al. 2023) and even among those with complex psychiatric needs (Anderson et al. 2020).”
Minorities’ diminished psychedelic returns: Cardio-metabolic health
Viña, S. M. (2024) · Drug Science Policy and Law · doi:10.1177/20503245231225756 · Cited by 10 · see citing works
“…have found that White individuals comprise over 80% of study participants, substantially underrepresenting BIPOC, and according to Thrul & Garcia-Romeu (2021), calls into question the generalizability of fi ndings to non-White populations (Garcia-Romeu et al., 2021; Michaels et al., 2018).”
Weleff, J., Nunes, J. C., Costa, G. P. A., Sofuoglu, M., MacLean, R. R., & Aquino, J. P. D. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16045 · Cited by 11 · see citing works
“94”
Butler, M., Bird, C., Maggio, C., Durden, A., Modlin, N. L., Campbell‐Coker, K., Edwards, M. J., Pick, S., Millman, L. S. M., Lowery, E., et al. (2024) · Wellcome Open Research · doi:10.12688/wellcomeopenres.22543.1 · Cited by 8 · see citing works
Psilocybin and chronic neuropathic pain: a systematic review
Jevotovsky, D. S., Chopra, H., Pak, D., Durbhakula, S., Shustorovich, A., Juneja, T., Broachwala, M. Y., AlFarra, T., Silver, C., Kreitzer, G., et al. (2024) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2024-105532 · Cited by 9 · see citing works
“61 Our analysis of 21 studies involving 697 chronic pain patients treated with psilocybin revealed promising results for chronic migraines, cluster headaches and unspecified chronic pain.”
Stroud, J., Rice, C., Orsini, A., Schlosser, M., Lee, J., Mandy, W., & Kamboj, S. K. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06685-8 · Cited by 10 · see citing works
“Participants’ average scores on the MEQ ( M = 63.5, SD = 22.7) and CEQ ( M = 22.68, SD = 20.16) were similar to values reported in previous clinical trials and questionnaire studies (e.g., MEQ: M = 65.4, SD = 24.2, CEQ: M = 30.1, SD = 17.4, Garcia-Romeu et al. 2021, Davis et al. 2020).”
InfluentialFive-year outcomes of psilocybin-assisted therapy for Major Depressive Disorder
Davis, A. K., DellaCrosse, M. A., Sepeda, N. D., Levin, A. W., Cosimano, M. P., Shaub, H., Washington, T., Gooch, P. M., Gilead, S., Gaughan, S. J., et al. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00461 · Cited by 9 · see citing works
Self-citationChing, T. H. W., Amoroso, L., Bohner, C., D’Amico, E. J., Eilbott, J. A., Entezar, T., Fitzpatrick, M., Fram, G., Grazioplene, R. G., Hokanson, J., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1278823 · Cited by 10 · see citing works
Klučková, T., Nikolič, M., Tylš, F., Viktorin, V., Vejmola, Č., Viktorinová, M., Bravermanová, A., Androvičová, R., Andrashko, V., Korčák, J., et al. (2025) · Pharmacological Reports · doi:10.1007/s43440-025-00742-5 · Cited by 8 · see citing works
“This is interesting in the context of the work of Garcia-Romeu et al. 2021 [60], who showed no significant effect of dose-adjusted effects, including weight and sex variables.”
Savoldi, R., Roazzi, A., & Sales, R. C. D. O. (2023) · International Journal for the Psychology of Religion · doi:10.1080/10508619.2023.2185369 · Cited by 8 · see citing works
“Moreover, a recent psilocybin study, tested across a wide range of body weights (49–113 kg), showed no evidence that body weight affected the subjective effects of this entheogen (Garcia-Romeu et al., 2021).”
BackgroundKnock, E., Siefried, K. J., Bedi, G., Albert, S., Day, R. O., Ezard, N., Ross, M., Liknaitzky, P., & Brett, J. (2025) · Addiction · doi:10.1111/add.70187 · Cited by 9 · see citing works
The pharmacological treatment of anxiety in people with eating disorders: A systematic review
Morris, R. C., Keeler, J. L., Treasure, J. L., & Himmerich, H. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107782 · Cited by 7 · see citing works
Ensuring psychedelic treatments and research do not leave anyone behind
Simon, M. A. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01710-4 · Cited by 7 · see citing works
Altman, B. M., & Magnus, M. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241278774 · Cited by 7 · see citing works
“…therapy is limited, given the underrepresentation of participants who are racial or ethnic minorities (Michaels et al., 2018), sexual and gender minorities (Stauffer et al., 2022), and individuals of lower socioeconomic status (Garcia-Romeu et al., 2021; Thrul and Garcia-Romeu, 2021).”
Thal, S. B., Wieberneit, M., Sharbanee, J. M., Skeffington, P., Bruno, R., Wenge, T., & Bright, S. J. (2023) · Journal of Humanistic Psychology · doi:10.1177/00221678231168516 · Cited by 7 · see citing works
Cavanna, F., Muller, S. L., de la Fuente, L. A., Zamberlán, F., Palmucci, M., Janeckova, L., Kuchař, M., Pallavicini, C., & Tagliazucchi, E. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.30.470657 · Cited by 7 · see citing works
“While this adjustment might not be necessary for larger doses, its importance for microdosing remains unexplored (Garcia-Romeu et al., 2021).”
BackgroundToward Standardized Products Containing Biomass of Psilocybe Cubensis Fungi
Foster, K., Morrison, I., Daniel, S., Antoine, J. M. R., Thankappan, B. M., Haye, W. D. L., Tyler, M. W., Grant, C. N., & Delgoda, R. (2025) · Journal of AOAC International · doi:10.1093/jaoacint/qsaf072 · Cited by 6 · see citing works
Syed, O. A., Petranker, R., & Tsang, B. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106204 · Cited by 6 · see citing works
Can the gut-brain axis provide insight into psilocybin's therapeutic value in reducing stress?
Kit, A., Conway, K., Makarowski, S., O'Regan, G., Allen, J., Shultz, S. R., Bodnar, T. S., & Christie, B. R. (2025) · Neurobiology of Stress · doi:10.1016/j.ynstr.2025.100732 · Cited by 5 · see citing works
The Potential Role of Psilocybin in Traumatic Brain Injury Recovery: A Narrative Review
Palmer, C., Ferber, A. T., & Greenwald, B. D. (2025) · Brain Sciences · doi:10.3390/brainsci15060572 · Cited by 5 · see citing works
Pilot study of psilocybin in patients with post-treatment lyme disease
Garcia‐Romeu, A., Naudé, G. P., Rebman, A. W., So, S., Yaffe, A., Geithner, I., Kozero, E. A., Yang, T., Soloski, M. J., & Aucott, J. N. (2026) · Scientific Reports · doi:10.1038/s41598-026-38091-9 · Cited by 5 · see citing works
“…trial data indicating substantial variability of response to psilocybin between individuals that was not accounted for by straightforward biological factors such as body weight or body mass index 83 , and superiority of ascending dose sequences in supporting overall improvements in well-being 78 .”
Self-citationExpectancies for Subjective and Antidepressant Effects in Psilocybin Users
Earleywine, M., Mian, M. N., & Leo, J. A. D. (2023) · Journal of Humanistic Psychology · doi:10.1177/00221678231194798 · Cited by 5 · see citing works
Syed, O. A., Tsang, B., Nestor, S. M., Lipsman, N., Husain, M. I., Alam, F., & Giacobbe, P. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106573 · Cited by 4 · see citing works
Tudorancea, I.-M., Stanciu, G. D., Torrent, C., Madero, S., Hriţcu, L., & Tamba, B.-I. (2025) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2025.2499458 · Cited by 4 · see citing works
“Additionally, the oldest participant in this analysis was 71, and the overall sample consisted of relatively healthy individuals, which limits generalis-ability to older populations (Garcia-Romeu et al. 2021).”
Viña, S. M. (2025) · Drug Science Policy and Law · doi:10.1177/20503245251337357 · Cited by 4 · see citing works
“This underrepresentation raises questions about the generalizability of fi ndings to non-White populations (Garcia-Romeu et al., 2021; Michaels et al., 2018; Thrul & Garcia-Romeu, 2021).”
Thomas, K. L. H., Jesse, R., Mehtani, N. J., Mitchell, J., & Anderson, B. T. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2201244 · Cited by 4 · see citing works
“To date, hundreds of research participants have been administered oral psilo-cybin at a dose of 30 mg per 70 kg (the weight of a “standard” healthy adult) (Garcia-Romeu et al. 2021; Garcia-Romeu, Kersgaard, and Addy 2016).”
BackgroundPsilocybin-assisted psychotherapy in adults with depression - A literature review.
Dorczok, M. C., Mittmann, G., Ettl, T., & Steiner-Hofbauer, V. (2025) · Progress in Neuro-psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111508 · Cited by 3 · see citing works
Ledwos, N., Baer, J., Husain, M. I., Blumberger, D. M., Patterson, R., Hollingdrake, E., Cheung, E. S. L., Hawco, C. S., Zrenner, C., Zrenner, B., et al. (2025) · BJPsych Open · doi:10.1192/bjo.2025.10895 · Cited by 3 · see citing works
How to set up a psychedelic study: Unique considerations for research involving human participants
Glennon, M. J., Bird, C., Yadav, P., Kleine, P., Suseelan, S., Boman-Markaki, C., Kotoula, V., Butler, M., Leech, R., Roseman, L., et al. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106657 · Cited by 5 · see citing works
Engel, L. B., Thal, S. B., Bright, S. J., & Low, M. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00377 · Cited by 3 · see citing works
Psychedelics: Old drugs, new trips
Rucker, J., & Seth, P. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211003495 · Cited by 3 · see citing works
Behavioural Investigations of Psilocybin in Animals 1962-2021: A Scoping ReviewPreprint
Shore, R., Dobson, K., Thomson, N., Barnim, N., Bergman, H. P., Rideout, K., McKeown, S., Olmstead, M. C., Goldie, C. E., & Dumont, É. C. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.04.574146 · Cited by 3 · see citing works
Beesley, V. L., Kennedy, T., Maccallum, F., Ross, M., Harvey, R., Rossell, S., Sarris, J., Perkins, D., Neale, R. E., Bennett-levy, J., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-095992 · Cited by 2 · see citing works
Psilocybin to promote synaptogenesis in the brains of patients with mild cognitive impairment
Song, J., Kambari, Y., Amaev, A., Ueno, F., Carmona, E. T., Luca, V. D., Pollock, B. G., Flint, A. J., Husain, M. I., Graff‐Guerrero, A., et al. (2023) · Medical Hypotheses · doi:10.1016/j.mehy.2023.111068 · Cited by 3 · see citing works
Complexities of psychedelics for therapeutic use in obesity and eating disorders
Reichelt, A. C. (2022) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.220135-l · Cited by 2 · see citing works
Meshkat, S., Fang, H., Sousa-Ho, R., Zeifman, R. J., Dunkley, B. T., Reichelt, A. C., Zhang, Y., Burback, L., Winkler, O., Greenshaw, A. J., et al. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0039 · Cited by 1 · see citing works
Vogt, S. B., & Liechti, M. E. (2025) · International review of neurobiology · doi:10.1016/bs.irn.2025.02.003 · Cited by 1 · see citing works
Hood, A., & Elkins, G. R. (2026) · Journal of Psychedelic Studies · doi:10.1556/2054.2026.00507 · Cited by 1 · see citing works
Psilocybin Modulates TPJ Effective Connectivity during Out-of-Body ExperiencesPreprint
Stoliker, D., Bernasconi, F., Blanke, O., & Razi, A. (2025) · medRxiv · doi:10.1101/2025.06.24.25330245 · Cited by 1 · see citing works
Et psykoanalytisk og et postmoderne perspektiv på selv/egoopløsning i en psykedelisk kontekstPreprint
Andersen, S. (2023) · doi:10.31234/osf.io/f26ce
Company on brink takes psilocybin to trial for fragile X syndrome
Hess, P. (2023) · The Transmitter · doi:10.53053/mkkk7368
Tetem, J., Fischmann, T., & Möller, T. J. (2023) · doi:10.31234/osf.io/ztyxh
use of psilocybin in the treatment of psychiatric disorders – review
Woźniak, J., BOGACZ, R., Gaik, M., Ewa, U. R. A. M., MAGDA, I., Womperski, K., & OSUCH, M. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.43.01.009
Progress in understanding the analgesic potential of ‘classic’ psychedelics
Andrassy, B., & Mukhdomi, T. J. (2023) · European Journal of Pain · doi:10.1002/ejp.2217
“Additionally, the standardization of dosing for psilocybin, the most common psychedelic in Cavarra, et al., was historically weight-based (Garcia-Romeu et al., 2021), but has since been established at ~ 25 mg due to a lack of differences between constant and weight-based doses (Garcia-Romeu et al.,…”
BackgroundVanderijst, L., Hever, F., Buot, A., Dauré, C., Benoit, J., Hanak, C., Veeser, J., Morgiève, M., Campanella, S., Kornreich, C., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3829237/v1
Is there mush-room to improve the environmental sustainability of psilocybin production?
Lanham, L., McTaggart, A. R., & Falconer, J. R. (2025) · Journal of CO2 Utilization · doi:10.1016/j.jcou.2025.103137
Behavioural investigations of psilocybin in non-human animals 1962–2021: A scoping review
Shore, R., Dobson, K., Thomson, N., Barnim, N., Bergman, H. P., Rideout, K., McKeown, S., Olmstead, M. C., Goldie, C. E., & Dumont, É. C. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00364
Henningfield, J. E., Barrett, F. S., Evans, S., Garcia-Romeu, A., Garrett, B. E., Hienz, R., Lukas, S., Nayak, S. M., Strain, E. C., Weerts, E., et al. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811251398801 · Cited by 1 · see citing works
“These and other design features to ensure safety in this study and subsequent studies are discussed further in this section and in other publications (Barrett et al., 2016; Garcia-Romeu et al., 2021; Henningfield et al., 2023; Johnson et al., 2008; Nayak and Zahid, 2025; Van Elk and Yaden, 2022).”
Self-citationNayak, S. M., Sepeda, N. D., Dick, M. N., Tiwari, P., Zahid, Z., Sayalı, C., Weiss, B., Yaden, D. B., Garcia‐Romeu, A., Barnett, B. S., et al. (2026) · medRxiv · doi:10.64898/2026.04.28.26351625
Self-citationBuczma, K., Kamińska, K., Kasarełło, K., Mirowska-Guzel, D. M., Andrzejuk, D., Kaczmarek, A., & Cudnoch‐Jędrzejewska, A. (2026) · Biomedicines · doi:10.3390/biomedicines14071516
Liu, C. J., Ho, E. M., Enos, A. S., Baublyte, U. B., Luna, I. M., Kosche, A. R., & Sohal, V. S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.05.736652
“In humans, doses ranging from 20-30 mg/70kg have similarly strong subjective effects 37 , which correspond to 60-66% 5HT2A receptor occupancy 36 .”
Signor, A., Comai, S., Pasut, G., Folli, F., Gentilucci, M., Gharavi, N., Raitsin, S., Nguyen, T. V., Pappagallo, M., Mattarei, A., et al. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70839
- Authors
- Garcia-Romeu, A., Barrett, F. S., Carbonaro, T. M., Johnson, M. W., & Griffiths, R. R.
- Affiliations
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- Johns Hopkins University (US)
- ORCID
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2021-02-20
- Volume
- 35
- Issue
- 4
- Pages
- 353-361
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- PMC
- PMC8056712
- OpenAlex
- W3129221857
- Cited by
- 96
- References
- 41
- Citations by year
- 2026: 10 · 2025: 22 · 2024: 19 · 2023: 21 · 2022: 16 · 2021: 8
- FWCI
- 10.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Psychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (R01DA003889)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psilocybin, dosage, weight-based dosing, fixed dose, body weight, subjective drug effects, mystical experience, major depressive disorder, mood disorders, substance use disorders
- MeSH terms
- Cigarette Smoking, Psychosocial Functioning, Adult, Affect, Body Weight, Major Depressive Disorder, Depressive Disorder, Major, Fear, Female, Grief, Hallucinogens, Humans, Male, Mysticism, Neoplasms, Psilocybin, Self-Assessment, Self Concept, Sex Factors, Treatment Outcome, Drug Monitoring, Drug Dosage Calculations, Serotonin 5-HT2 Receptor Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
